Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Human Genome Sciences And GlaxoSmithKline Announce Positive Phase 3 Study Results For BENLYSTA(TM) In Systemic Lupus Erythematosus
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that belimumab plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.

Virtual Doctors Visits Satisfactory For Both Patients And Clinicians
Travelers book plane tickets online, bank customers can check their accounts at any computer, and busy families can grocery shop online. Someday, even doctor visits could be among the conveniences offered via the Internet. Researchers considering the feasibility and effectiveness of virtual doctors visits report that patients and physicians found that evaluations done through videoconferencing were similar to face-to-face visits on most measures, according a study published in the May issue of the Journal of Telemedicine and Telecare.
News of the day
The Protein CCKR2: A Potential Drug Target For Colorectal Cancer?
Colorectal cancer, the second most common cause of death from cancer in the United States, is associated with an abnormally high rate of increase in the number of cells lining the colon (colonic hyperproliferation). In mice, overexpression of the human protein progastrin has been shown to cause colonic hyperproliferation and promote colorectal cancer, but the molecular mechanisms underlying this have remained undetermined.
Public Health

Scottsdale Healthcare Is West's Only Clinical Research Site For "Dream Team" Pancreatic Cancer Research Studies

Scottsdale Healthcare, through its strategic alliance with the Translational Genomics Research Institute (TGen), is one of three clinical research sites in the United States that will participate in a three-year investigation into new approaches to treating pancreatic cancer, the fourth leading cause of cancer death in the U.S. The clinical trials will be designed to deprive pancreatic tumors of crucial nutrients, thereby cutting off the fuel supply. Understanding the cell"s fuel supply will help scientists develop more individualized treatments with fewer side effects. Scottsdale Healthcare became a primary clinical research site for TGen in 2005, a strategic alliance resulting in creation of TCRS, which is housed in the Virginia G. Piper Cancer Center at Scottsdale Healthcare. Cancer patients from across the U.S. and other countries regularly travel to Scottsdale Healthcare to participate in groundbreaking clinical trials. The Scottsdale Healthcare-TGen alliance facilitates bench-to-bedside application of new research discoveries in patients with advanced cancer. Other clinical research sites in the study are the University of Pennsylvania in Philadelphia and John Hopkins University in Baltimore. Scottsdale Healthcare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009